What question did this study set out to answer?

The research aims to gather data on blastic plasmacytoid dendritic cell neoplasm (BPDCN) patients and analyze incidence, clinical presentations, and treatment strategies.

February 6, 2026Open Access

Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature

View Full Paper

Ask AI

Bookmark

Authors

RMRamona MeierUniversity Hospital Regensburg CSCosima SuterUniversity of Lucerne TPThomas Pabst

Discussion

Member takes

Implication

Case series examines outcomes in a rare blood cancer, highlighting treatment strategies and prognosis.

Key Points

The research aims to gather data on blastic plasmacytoid dendritic cell neoplasm (BPDCN) patients and analyze incidence, clinical presentations, and treatment strategies.
Collected data from Swiss haemato-oncology centers from 2005 to 2022
Reviewed published literature from 1997 to 2020
Analyzed demographics and treatment outcomes
Evaluated response to therapies in Swiss cohort
Identified 115 publications with 600 patients worldwide
Median age at diagnosis was 66.5 years
Allogenic transplantation and ALL regimens showed the best outcomes
Median overall survival in Swiss cohort was 1.2 years
Eight patients received tagraxofusp, a new treatment option

Cite This Study

Meier et al. (2025) studied this question.

synapsesocial.com/papers/698585678f7c464f23008af6 https://doi.org/10.5167/uzh-284596

View Full Paper

Ask AI

Bookmark

Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature

Discussion

Member takes

Implication

Key Points

Cite This Study

Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider